These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 6751241)
1. Clinical response to therapy with thymopoietin pentapeptide (TP-5) in rheumatoid arthritis. Veys EM; Huskisson EC; Rosenthal M; Vischer TL; Mielants H; Thrower PA; Scott J; Ott H; Scheijgrond H; Symoens J Ann Rheum Dis; 1982 Oct; 41(5):441-3. PubMed ID: 6751241 [TBL] [Abstract][Full Text] [Related]
2. Thymopoietin pentapeptide (thymopentin, TP-5) in the treatment of rheumatoid arthritis. A compilation of several short- and longterm clinical studies. Veys EM; Mielants H; Verbruggen G; Spiro T; Newdeck E; Power D; Goldstein G J Rheumatol; 1984 Aug; 11(4):462-6. PubMed ID: 6384507 [TBL] [Abstract][Full Text] [Related]
3. Interim results on the clinical effects of i.v. administered thymopentin in active rheumatoid arthritis. Malaise M; Franchimont P; Hauwaert C; Danneskiold-Samsoe B; Gross D; Gerber H; Gerschpacher H; Bolla K Int J Clin Pharmacol Res; 1984; 4(6):451-7. PubMed ID: 6398314 [TBL] [Abstract][Full Text] [Related]
4. Treatment of active rheumatoid arthritis with slow intravenous injections of thymopentin. A double-blind placebo-controlled randomised study. Malaise MG; Hauwaert C; Franchimont P; Danneskiold-Samsoe B; Bach-Andersen R; Gross D; Gerber H; Gerschpacher H; Stocker H; Bolla K Lancet; 1985 Apr; 1(8433):832-6. PubMed ID: 2858708 [TBL] [Abstract][Full Text] [Related]
5. Some observations on various dose regimens of thymopentin treatment in rheumatoid arthritis. Molin L; Schmid F; Bolla K Surv Immunol Res; 1985; 4 Suppl 1():76-80. PubMed ID: 3898296 [TBL] [Abstract][Full Text] [Related]
6. Confirmative study of the effectiveness of thymopentin in active rheumatoid arthritis. Malaise M; Franchimont P; Hauwaert C; Danneskiold-Samsoe B; Gross D; Gerber H; Gerschpacher H; Bolla K Surv Immunol Res; 1985; 4 Suppl 1():87-93. PubMed ID: 3898298 [TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of various routes of administration of thymopentin (TP-5) with consideration of degradative mechanisms. Audhya T; Goldstein G Int J Pept Protein Res; 1983 Aug; 22(2):187-93. PubMed ID: 6352534 [TBL] [Abstract][Full Text] [Related]
8. Thymopentin (TP-5) potency in vivo is enhanced by slow infusion. Audhya T; Goldstein G Int J Pept Protein Res; 1983 Nov; 22(5):568-72. PubMed ID: 6360927 [TBL] [Abstract][Full Text] [Related]
9. Thymopentin: stability considerations and potency by various routes of administration. Audhya TK; Goldstein G Surv Immunol Res; 1985; 4 Suppl 1():17-23. PubMed ID: 3898289 [TBL] [Abstract][Full Text] [Related]
10. First observations on high-dosed and long-term thymopentin treatment in active rheumatoid arthritis. Molin L; Schmid F; Bolla K Int J Clin Pharmacol Res; 1984; 4(6):445-9. PubMed ID: 6398313 [TBL] [Abstract][Full Text] [Related]
11. [Immunomodulating therapy in chronic polyarthritis with thymopentin. A multicenter placebo-controlled study of 119 patients]. Lemmel EM; Bach GL; Bolten W; Brackertz D; Fahmy Z; Mattern H; Stroehmann I; Wittenborg A Dtsch Med Wochenschr; 1988 Feb; 113(5):172-6. PubMed ID: 3276492 [TBL] [Abstract][Full Text] [Related]
12. Thymopentin (TP-5) in the treatment of rheumatoid arthritis. Kantharia BK; Goulding NJ; Hall ND; Davies J; Maddison PJ; Bacon PA; Farr M; Wojtulewski JA; Englehart KM; Liyanage SP Br J Rheumatol; 1989 Apr; 28(2):118-23. PubMed ID: 2650797 [TBL] [Abstract][Full Text] [Related]
13. [Telethermographic evaluation of the intra-articular administration of thymopentin in rheumatoid arthritis of the knee]. Pappalardo A; Sallì L; Campisi D; Scalici G; Di Marco C; Martorana U Clin Ter; 1989 Mar; 128(5):321-7. PubMed ID: 2524320 [TBL] [Abstract][Full Text] [Related]
14. Treatment of cutaneous T-cell lymphomas with TP-5. Evaluation of the clinical effect in 8 patients. Przybilla B; Burg G; Schmoeckel C; Braun-Falco O Acta Derm Venereol; 1983; 63(6):524-9. PubMed ID: 6198843 [TBL] [Abstract][Full Text] [Related]
15. Thymopoietin pentapeptide (TP-5) improves clinical parameters and lymphocyte subpopulations in atopic dermatitis. Kang K; Cooper KD; Hanifin JM J Am Acad Dermatol; 1983 Mar; 8(3):372-7. PubMed ID: 6339571 [TBL] [Abstract][Full Text] [Related]
16. Thymopentin as adjuvant to hepatitis B vaccination. Results from three double-blind studies. Grob PJ; Binswanger U; Blumberg A; Gloor HJ; Hany A; Herwig W; Iselin H; Zàruba K; Bolla K Surv Immunol Res; 1985; 4 Suppl 1():107-15. PubMed ID: 3898281 [TBL] [Abstract][Full Text] [Related]
17. Thymopoietin pentapeptide treatment of primary immunodeficiencies. Aiuti F; Businco L; Fiorilli M; Galli E; Quinti I; Rossi P; Seminara R; Goldstein G Lancet; 1983 Mar; 1(8324):551-4. PubMed ID: 6131256 [TBL] [Abstract][Full Text] [Related]
18. Effect of thymopoietin pentapeptide on low reversible E-rosette forming cells of rheumatoid arthritis patients. -I) In vitro study. Auteri A; Laghi Pasini F; Pasqui AL; Bilenchi R; Di Perri T Boll Soc Ital Biol Sper; 1980 Feb; 56(4):308-11. PubMed ID: 7018514 [No Abstract] [Full Text] [Related]
19. Therapy with thymopoietin pentapeptide (TP-5) in 26 patients with primary immunodeficiencies. Aiuti F; Businco L; Fiorilli M; Galli E; Quinti I; Le Moli S; Seminara R; Goldstein G Birth Defects Orig Artic Ser; 1983; 19(3):267-72. PubMed ID: 6360238 [No Abstract] [Full Text] [Related]
20. Thymopentin in the treatment of juvenile chronic arthritis. Bardare M; Corona F; Ogliari MT; Cohen E Clin Exp Rheumatol; 1990; 8(1):89-93. PubMed ID: 1971780 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]